Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006–2015)

References

• Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology. 2013;145:158–165 e2.
   PubMed Web of Science ®Google Scholar
• Thia KT, Loftus EV, Jr., Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167–3182.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727.
   PubMed Web of Science ®Google Scholar
• Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26:811–817.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.
   PubMed Web of Science ®Google Scholar
• Park KT, Colletti RB, Rubin DT, et al. Health insurance paid costs and drivers of costs for patients With Crohn's disease in the United States. Am J Gastroenterol. 2016;111:15–23.
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63:72–79.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Katzka DA. Enhancing high value care in gastroenterology practice. Clin Gastroenterol Hepatol. 2016;14:1376–1384.
   PubMed Web of Science ®Google Scholar
• Patel K, Presser E, George M, et al. Shifting away from fee-for-service: alternative approaches to payment in gastroenterology. Clin Gastroenterol Hepatol. 2016;14:497–506.
   PubMed Web of Science ®Google Scholar
• Limsrivilai J, Stidham RW, Govani SM, et al. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15:385–392 e2.
   PubMed Web of Science ®Google Scholar
• Prenzler A, Bokemeyer B, von der Schulenburg JM, et al. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ. 2011;12:273–283.
   PubMed Web of Science ®Google Scholar
• Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.
   PubMed Web of Science ®Google Scholar
• Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis. 2015;21:121–131.
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen MJ, Severs M, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11:e0142481.
   PubMed Web of Science ®Google Scholar
• Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719–728.
   PubMed Web of Science ®Google Scholar
• Mak LY, Ng SC, Wong IOL, et al. Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis. J Gastroenterol Hepatol. 2018;33:141–149.
   PubMed Web of Science ®Google Scholar
• Kim JW, Lee CK, Rhee SY, et al. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: a nationwide population-based study. J Gastroenterol Hepatol. 2018;33:847–854.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17:5–14.
   PubMed Web of Science ®Google Scholar
• Kim M, Choi KH, Hwang SW, et al. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study. J Am Acad Dermatol. 2017;76:40–48.
   PubMed Web of Science ®Google Scholar
• Lee YH, Han K, Ko SH, et al. Data analytic process of a nationwide population-based study using national health information database established by national health insurance service. Diabetes Metab J. 2016;40:79–82.
   PubMed Web of Science ®Google Scholar
• Jung YS, Han M, Kim WH, et al. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011-2014: a nationwide population-based study. Dig Dis Sci. 2017;62:2102–2112.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.
   PubMed Web of Science ®Google Scholar
• Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471–1478.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Longobardi T, Finlayson G, et al. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012;18:1498–1508.
   PubMed Web of Science ®Google Scholar
• Shota S, Kyoko N, Kenji S, et al. Paradigm shift of healthcare cost for patients with inflammatory bowel diseases: a claims data-based analysis in Japan. Gastrointest Disord. 2019;1:120–128.
   Google Scholar
• Xu JJ, Tang MY, Shen J. Trends and factors affecting hospitalization costs in patients with inflammatory bowel disease: a two-center study over the past decade. Gastroenterol Res Pract. 2013;2013:1.
   Web of Science ®Google Scholar
• Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:62–68.
   PubMed Web of Science ®Google Scholar
• Hait E, Hait L, Bousvaros A, et al. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm Bowel Dis. 2005;11:519–527.
   PubMed Web of Science ®Google Scholar
• Severs M, Oldenburg B, van Bodegraven AA, et al. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017;11:289–296.
   PubMed Web of Science ®Google Scholar
• IBD biological therapy audit. National clinical audit of biological therapies - Annual report 2016. [cited 2016 Sept 22]. Available from: https://www.rcplondon.ac.uk/projects/outputs/national-clinical-audit-biological-therapies-annual-report-2016
   Google Scholar
• Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease–modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76–87.
   PubMed Web of Science ®Google Scholar
• Doherty G, Katsanos KH, Burisch J, et al. European Crohn's and colitis organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease. J Crohns Colitis. 2018;12:17–31.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm Bowel Dis. 2015;21:623–630.
   PubMed Web of Science ®Google Scholar
• Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48:196–205.
   PubMed Web of Science ®Google Scholar
• Bae JM, Kim M, Lee HH, et al. Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study. J Invest Dermatol. 2018;138:768–774.
   PubMed Web of Science ®Google Scholar
• Shin DW, Cho B, Guallar E. Korean national health insurance database. JAMA Intern Med. 2016;176:138.
   PubMed Web of Science ®Google Scholar
• Shin DW, Cho J, Yang HK, et al. Impact of continuity of care on mortality and health care costs: a nationwide cohort study in Korea. Ann Fam Med. 2014;12:534–541.
   PubMed Web of Science ®Google Scholar